IS6133A - Samsett salt af amlódipíni og atórvastatíni - Google Patents
Samsett salt af amlódipíni og atórvastatíniInfo
- Publication number
- IS6133A IS6133A IS6133A IS6133A IS6133A IS 6133 A IS6133 A IS 6133A IS 6133 A IS6133 A IS 6133A IS 6133 A IS6133 A IS 6133A IS 6133 A IS6133 A IS 6133A
- Authority
- IS
- Iceland
- Prior art keywords
- amlodipine
- atorvastatin
- composite salt
- composite
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13626999P | 1999-05-27 | 1999-05-27 | |
| PCT/IB2000/000590 WO2000073271A1 (en) | 1999-05-27 | 2000-05-08 | Mutual salt of amlodipine and atorvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS6133A true IS6133A (is) | 2001-10-30 |
Family
ID=22472108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6133A IS6133A (is) | 1999-05-27 | 2001-10-30 | Samsett salt af amlódipíni og atórvastatíni |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6262092B1 (is) |
| EP (1) | EP1180097B1 (is) |
| JP (1) | JP2003500473A (is) |
| KR (1) | KR20020019450A (is) |
| CN (1) | CN1373753A (is) |
| AP (1) | AP2001002347A0 (is) |
| AR (1) | AR028994A1 (is) |
| AT (1) | ATE367376T1 (is) |
| AU (1) | AU4138200A (is) |
| BG (1) | BG106128A (is) |
| BR (1) | BR0011008A (is) |
| CA (1) | CA2375225C (is) |
| DE (1) | DE60035581T2 (is) |
| EA (1) | EA200101132A1 (is) |
| EE (1) | EE200100632A (is) |
| ES (1) | ES2287009T3 (is) |
| GT (1) | GT200000077A (is) |
| HN (1) | HN2000000050A (is) |
| HR (1) | HRP20010857A2 (is) |
| HU (1) | HUP0202070A3 (is) |
| IL (1) | IL145837A0 (is) |
| IS (1) | IS6133A (is) |
| MA (1) | MA26739A1 (is) |
| MX (1) | MXPA01012126A (is) |
| NO (1) | NO20015757L (is) |
| OA (1) | OA11951A (is) |
| PA (1) | PA8494501A1 (is) |
| PE (1) | PE20010168A1 (is) |
| PL (1) | PL352828A1 (is) |
| SK (1) | SK16802001A3 (is) |
| TN (1) | TNSN00110A1 (is) |
| TR (1) | TR200103411T2 (is) |
| UA (1) | UA56363C2 (is) |
| UY (1) | UY26163A1 (is) |
| WO (1) | WO2000073271A1 (is) |
| ZA (1) | ZA200109693B (is) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| US20050119270A1 (en) * | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
| US6835742B2 (en) * | 2000-08-04 | 2004-12-28 | R. Preston Mason | Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release |
| GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
| US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| DE10140421A1 (de) * | 2001-08-17 | 2003-03-06 | Bayer Ag | Neue Kombination |
| US6680334B2 (en) | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
| WO2003035046A2 (en) * | 2001-10-18 | 2003-05-01 | Novartis Ag | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| CN1152013C (zh) * | 2001-11-22 | 2004-06-02 | 张喜田 | 一类左旋氨氯地平盐的水合物及其制剂 |
| US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US6699892B2 (en) | 2002-06-04 | 2004-03-02 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salt of amlodipine and method of preparing the same |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| KR100462304B1 (ko) * | 2002-07-30 | 2004-12-17 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100496436B1 (ko) * | 2002-07-30 | 2005-06-20 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| WO2005097191A2 (en) * | 2004-04-04 | 2005-10-20 | Sepracor Inc. | COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION |
| CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20100029743A1 (en) * | 2006-09-27 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| US20090042849A1 (en) * | 2006-12-06 | 2009-02-12 | Yochai Birnbaum | Phosphorylation of 5-lipoxygenase at ser523 and uses thereof |
| JP2018516624A (ja) * | 2015-04-15 | 2018-06-28 | コンシーヴァルブ エルエルシー | 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法 |
| CN105012258B (zh) * | 2015-08-06 | 2017-11-03 | 北京嘉林药业股份有限公司 | 阿托伐他汀钙和氨氯地平片剂的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5155120A (en) | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. |
-
2000
- 2000-04-12 HN HN2000000050A patent/HN2000000050A/es unknown
- 2000-04-25 PA PA20008494501A patent/PA8494501A1/es unknown
- 2000-05-08 ES ES00920978T patent/ES2287009T3/es not_active Expired - Lifetime
- 2000-05-08 SK SK1680-2001A patent/SK16802001A3/sk unknown
- 2000-05-08 AP APAP/P/2001/002347A patent/AP2001002347A0/en unknown
- 2000-05-08 HU HU0202070A patent/HUP0202070A3/hu unknown
- 2000-05-08 EE EEP200100632A patent/EE200100632A/xx unknown
- 2000-05-08 OA OA1200100313A patent/OA11951A/en unknown
- 2000-05-08 DE DE60035581T patent/DE60035581T2/de not_active Expired - Fee Related
- 2000-05-08 IL IL14583700A patent/IL145837A0/xx unknown
- 2000-05-08 MX MXPA01012126A patent/MXPA01012126A/es active IP Right Grant
- 2000-05-08 TR TR2001/03411T patent/TR200103411T2/xx unknown
- 2000-05-08 AU AU41382/00A patent/AU4138200A/en not_active Abandoned
- 2000-05-08 AT AT00920978T patent/ATE367376T1/de not_active IP Right Cessation
- 2000-05-08 EP EP00920978A patent/EP1180097B1/en not_active Expired - Lifetime
- 2000-05-08 JP JP2000621338A patent/JP2003500473A/ja active Pending
- 2000-05-08 KR KR1020017015184A patent/KR20020019450A/ko not_active Application Discontinuation
- 2000-05-08 BR BR0011008-6A patent/BR0011008A/pt not_active Application Discontinuation
- 2000-05-08 CA CA002375225A patent/CA2375225C/en not_active Expired - Fee Related
- 2000-05-08 EA EA200101132A patent/EA200101132A1/ru unknown
- 2000-05-08 PL PL00352828A patent/PL352828A1/xx not_active Application Discontinuation
- 2000-05-08 CN CN00808121A patent/CN1373753A/zh active Pending
- 2000-05-08 WO PCT/IB2000/000590 patent/WO2000073271A1/en active IP Right Grant
- 2000-05-24 US US09/578,204 patent/US6262092B1/en not_active Expired - Fee Related
- 2000-05-24 MA MA25989A patent/MA26739A1/fr unknown
- 2000-05-24 TN TNTNSN00110A patent/TNSN00110A1/fr unknown
- 2000-05-25 UY UY26163A patent/UY26163A1/es not_active Application Discontinuation
- 2000-05-25 PE PE2000000499A patent/PE20010168A1/es not_active Application Discontinuation
- 2000-05-25 GT GT200000077A patent/GT200000077A/es unknown
- 2000-05-26 AR ARP000102584A patent/AR028994A1/es not_active Application Discontinuation
- 2000-08-05 UA UA2001118092A patent/UA56363C2/uk unknown
-
2001
- 2001-10-30 IS IS6133A patent/IS6133A/is unknown
- 2001-11-19 HR HR20010857A patent/HRP20010857A2/hr not_active Application Discontinuation
- 2001-11-21 BG BG106128A patent/BG106128A/xx unknown
- 2001-11-26 ZA ZA200109693A patent/ZA200109693B/en unknown
- 2001-11-26 NO NO20015757A patent/NO20015757L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6133A (is) | Samsett salt af amlódipíni og atórvastatíni | |
| DK1189582T3 (da) | Kompositmaterialer af calciumforbindelser og proteinkomponenter | |
| DK1411923T3 (da) | Farmaceutisk sammensætning af amlodipin og atorvastatin | |
| NO20041975D0 (no) | Bicyklisk oksopyridin og oksopyrimidinderivater | |
| NO20032753L (no) | Forbindelse og anvendelse derav | |
| DK1400518T3 (da) | Heterocycliske forbindelser og lægemidler | |
| NO20024874D0 (no) | Benzoamidpiperidin-holdige forbindelser og beslektede forbindelser | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| NO20010446D0 (no) | Substituert anilidforbindelser og metoder | |
| NO20003928D0 (no) | Støtbarriere og barriere-element | |
| NO983187L (no) | Substituerte aza- og diazacykloheptan og -cyklooktan-forbindelse og deres anvendelse | |
| NO20003067D0 (no) | Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling | |
| IS5345A (is) | Samsett meðferð sem inniheldur amlódipín og statín efnasambönd | |
| IS6135A (is) | Samsett forlyf af amlódipíni og atorvastatíni | |
| DK1214961T3 (da) | Krystallisationsapparat og krystallisationsmetode | |
| NO20006059L (no) | Sammensatt element og fremgangsmåte for anvendelse | |
| NO20013085D0 (no) | Fosfororganiske forbindelser og deres anvendelse | |
| IS6118A (is) | Samvirk áhrif amlódípíns og atórvastatíns | |
| NO20032821D0 (no) | Sea-trosy og beslektede fremgangsmåter | |
| NO20042539L (no) | Amlodipin saltformer og fremgangsmåter for fremstilling derav | |
| NO20014454D0 (no) | Konstruksjon og anvendelse av samme | |
| DK1127274T3 (da) | Detektor og deres anvendelse | |
| DK1080081T3 (da) | Benzofuroxanderivater og anvendelse deraf til behandling af angina pectoris | |
| GB0027410D0 (en) | Mutual prodrug of amlodipine and atorvastatin | |
| SI1180102T1 (en) | Mutual prodrugs of amlodipine and atorvastatin |